Six months ago, a National Particle Therapy Symposium was held in Adelaide, Australia. This symposium emphasized the need for a continued, unified, and collaborative approach for the introduction of particle therapy in Australia, as the construction of the Australian Bragg Centre (ABC) for Proton Therapy and Research in Adelaide and the installation of the Radiance 330® Proton Therapy System nears.
On May 5, 2022 Massachusetts General Hospital will host a virtual Proton Therapy Symposium. Mass General will feature experts from various specialties who will speak to their 60 years of proton therapy experience and share insight on practical applications of proton therapy for commonly treated disease sites in adults and children. Register here.
As a proton equipment provider for Mass General, ProTom has allowed Mass General to expand their proton treatment program utilizing the Radiance 330 single room proton system.
ProTom strongly believes in collaboration in design and function of proton therapy equipment to fit the customer’s needs and to serve their patients. Our team specializes in customization to ensure the equipment fits the customer. Mass General has highly-skilled proton therapy team, and ProTom delivered the highly specialized proton therapy system they demanded. ProTom is providing the same level of customization for the Australi]an Bragg Centre.
About Massachusetts General Hospital
Massachusetts General Hospital is the original and largest teaching hospital of Harvard Medical School located in Boston, Massachusetts. It is the oldest and largest hospital in New England and the third oldest general hospital in United States. Mass General’s 999-bed medical center offers sophisticated diagnostic and therapeutic care in virtually every specialty and subspecialty of medicine and surgery, while four health centers provide high-quality care and services in the surrounding community.
About ProTom International
ProTom International Holding Corporation is a medical technology company focused on proton beam therapy for patients with cancer. ProTom assembles, tests, sells and distributes the Radiance 330 Proton Therapy System, which has FDA 510(k) clearance for commercial distribution in the United States. We are steadfast in our mission to transform cancer treatment by expanding the accessibility of proton therapy and by developing proton tomography technology. Combined with the fast return on investment, the precision of pencil beam scanning and power of integrated imaging, ProTom’s Radiance 330 proton therapy system is the choice for proton therapy technology.